Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2022
[Japanese GAAP]
August 8, 2022 | |||||
Company name: | Medical Data Vision Co., Ltd. | Listing: Tokyo Stock Exchange | |||
Securities code: | 3902 | URL https://www.mdv.co.jp/ | |||
Representative: | (Title) President | (Name) Hiroyuki Iwasaki | |||
Inquiries: | (Title) Executive Officer and General Manager of | (Name) Masahiro Kihara | Tel: +81-3-5283-6911 | ||
Corporate Planning Division | |||||
Scheduled date to file quarterly report: | August 9, 2022 | ||||
Scheduled date to commence dividend payments: | - | ||||
Preparation of supplementary material on quarterly financial results : Yes | |||||
Holding of quarterly financial results briefing | : Yes (for institutional investors and analysts) | ||||
(Yen amounts are rounded down to millions, unless otherwise noted) |
1. Consolidated financial results for the second quarter of the fiscal year ending December 31, 2022 (from January 1, 2022 to June 30, 2022)
(1) Consolidated operating results | (cumulative) | (Percentages indicate year-on-year changes) | |||||||||||
Net sales | Operating income | Ordinary income | Net income attributable | ||||||||||
to owners of parent | |||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | ||||||
Second quarter of FY | |||||||||||||
ending December 31, 2022 | 2,856 | - | 785 | - | 776 | - | 522 | - | |||||
Second quarter of FY ended | |||||||||||||
December 31, 2021 | 2,635 | 28.8 | 720 | 51.4 | 719 | 50.8 | 484 | 51.7 | |||||
(Note) Comprehensive income | Second quarter of fiscal year ending December 31, 2022 | 522 million yen [-%] | |||||||||||
Second quarter of fiscal year ended December 31, 2021 | 499 million yen [56.3%] | ||||||||||||
Basic earnings per share | Diluted earnings per share | ||||||||||||
Yen | Yen | ||||||||||||
Second quarter of FY | |||||||||||||
ending December 31, 2022 | 13.65 | 13.64 | |||||||||||
Second quarter of FY ended | |||||||||||||
December 31, 2021 | 12.32 | - |
(Note) 1.The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. Consolidated earnings for the 2nd quarter of the fiscal year ending December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.
2. Diluted earnings per share for the six months ended June 30, 2021 are not presented as there are no potential shares.
- Consolidated financial position
Total assets | Net assets | Equity-to-asset ratio | ||||
Millions of yen | Millions of yen | % | ||||
As of June30, 2022 | ||||||
(2Q FY2022) | 4,675 | 3,279 | 68.2 | |||
As of December 31, 2021 | ||||||
(FY2021) | 5,534 | 4,205 | 75.1 | |||
(Reference) Equity | As of June 30, 2022 | 3,186 million yen | ||||
As of December 31, 2021 | 4,156 million yen |
2. Cash dividends
Annual dividends per share | ||||||
First quarter-end | Second quarter-end | Third quarter-end | Fiscal year-end | Total | ||
Yen | Yen | Yen | Yen | Yen | ||
FY ended | ||||||
December 31, 2021 | - | 0.00 | - | 5.60 | 5.60 | |
FY ending | ||||||
December 31, 2022 | - | 0.00 | ||||
FY ending | ||||||
December 31, 2022 | ||||||
(forecast) | - | 6.00 | 6.00 |
(Note) Revision of the latest released dividend forecast : None
1
3. Consolidated earnings forecasts for the fiscal year ending December 31, 2022 (from January 1, 2022 to December 31, 2022)
(Percentages indicate year-on-year changes)
Net sales | Operating income | Ordinary income | Net income attributable | Basic earnings | |||||||||
to owners of parent | per share | ||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | |||||
Full year | 6,300 | - | 1,599 | - | 1,600 | - | 1,098 | - | 28.74 |
(Notes) 1. Revision of the latest released earnings forecasts | : None |
- The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. The above consolidated earnings forecasts therefore are the amount after applying such accounting standard and related implementation guidance, presenting no year-on-year changes.
- The Company purchased 763,400 treasury shares from January 1, 2022 to January 25, 2022 based on the resolution of the Board of Directors held on December 22, 2021. Basic earnings per share for the consolidated earnings forecasts takes into account the impact of the purchase of treasury shares.
* Notes
(1) Changes in significant subsidiaries during the three months ended March 31, 2022 (changes in specified subsidiaries resulting in changes in
scope of consolidation) : None | |||
Newly included: - companies (Company name) | , Excluded: - companies (Company name) | ||
(2) | Application of special accounting treatment to the preparation of quarterly consolidated financial statements | : None | |
(3) | Changes in accounting policies, changes in accounting estimates, and restatement | ||
(i) Changes in accounting policies due to revisions to accounting standards and other regulations | : Yes |
- Changes in accounting policies other than (i) above : None
(iii) | Changes in accounting estimates | : None |
(iv) | Restatement | : None |
(Notes) For more details, please refer to "(4) Notes to quarterly consolidated financial statements (Change in accounting policies) in 2. Quarterly consolidated financial statements and Key notes" on page 5 of the attached materials.
- Number of issued shares (common shares)
- Total number of issued shares at the end of the period (including treasury shares)
- Number of treasury shares at the end of the period
- Average number of shares outstanding during the period (cumulative quarterly period )
As of June 30, 2022 | 40,027,526 shares | As of December 31, | 40,027,526 shares |
2021 | |||
As of June 30, 2022 | 1,830,678 shares | As of December 31, | 1,067,278 shares |
2021 | |||
Second quarter of FY | Second quarter fiscal | ||
ending December 31, | 38,272,311 shares | year ended December | 39,299,332 shares |
2022 | 31, 2021 |
- Quarterly financial results reports are exempt from a quarterly review conducted by certified public accountants or an audit corporation.
- Proper use of earnings forecasts, and other special matters
The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable.
2
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Medical Data Vision Co. Ltd. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 03:15:05 UTC.